MedTrace Logo

Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

NCT00395707 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2009-02-09

No results posted yet for this study

Summary

The primary objective of this study is to determine the safety \& efficacy of ranibizumab for the treatment of retinal angiomatous proliferation secondary to age related macular degeneration.

Conditions

  • Macular Degeneration

Interventions

DRUG

Lucentis

0.3mg/0.05 ml or 0.5mg/0.05 ml

DRUG

Ranibizumab

0.3mg/0.05 ml or 0.5mg/0.05 ml

DRUG

Ranibizumab (Lucentis)

0.3mg/0.05 ml intravitreally

DRUG

Ranibizumab (Lucentis)

0.5mg/0.05 ml

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • The National Retina Institute

    lead OTHER

Principal Investigators

  • Thomas M Johnson, MD · National Retina Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00395707 on ClinicalTrials.gov